Felicia Sideris – 2021-07-27T07:12:00.000+02:00
Going back to the source cited by this Internet user, we find an interview with the president of Sanofi France, Olivier Bogillot. Asked this Sunday, July 25 on Europe 1, he returned to the delay taken by the French company in the race for the vaccine against the Covid-19. Promising that there will be alright “a French vaccine” before the end of the year, he returned to the trade-offs made by the company when it launched its research. “We do not choose messenger RNA, because until Covid-19, it has never been proven, we do not know if it will work”, he explains. Since then “when doing [le] choice” of the technology that will be used for a vaccine candidate, the researchers prefer to look at the recombinant proteins. “We are making this choice because we have mastered this technology.”
defends the ambition of information
verified and accessible to all thanks to the income of the
To help us maintain this free service you can “change your choice” and accept all cookies.
MODIFY AND ACCEPT ALL